A division of Teradata medication in Australia.

Claraview reports successful deployment of Business Data Integrity solution for Affinity Health Plan Claraview, a division of Teradata , a strategy and technology consultancy focused exclusively on business cleverness and analytic solutions, announced today the successful deployment of the Enterprise Data Integrity alternative for Affinity Health Program. The EDI solution will provide a ‘single source of truth’ via an enterprise-level standardization of data components, definitions and code schemes to aid consistent and accurate analytics across the enterprise medication in Australia . As part of a multi-phased plan, Affinity Health Plan’s Information Management section rolled out the 1st stage of the EDI solution in January 2012.

By particularly targeting effector memory T-cells and leaving additional components of the immune system intact, PAP-1 has the potential to offer the efficacy of topical steroids while staying away from their side-effects.’ ‘Out-licensing topical PAP-1 is a major milestone for Airmid, and we are delighted to possess attracted a group of Circassia’s high caliber to advance the development of the important therapeutic,’ said Dr George Miljanich, CEO of Airmid. ‘We anticipate Circassia’s success, that will further validate this class of novel molecules as a highly promising source of secure and efficient medicines.’.. Circassia acquires global privileges to novel topical therapeutic for psoriasis and atopic dermatitis Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization privileges to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1.